

## Waters and BioInfra establish ASEAN Academy for Bioanalysis in Korea

21 June 2022 | News

**Companies collaborate to promote the development of bioanalytical skills to enhance regional scientific competitiveness and the quality of pharmaceutical research and testing**



Waters Corporation has announced a collaboration with BioInfra, a pioneering contract research organization (CRO) company for the pharmaceutical and clinical fields, to jointly establish the ASEAN Academy for Bioanalysis. The academy is dedicated to providing scientists with the hands-on knowledge required to design and perform a variety of bioanalytical methods, which are vital throughout every stage of drug discovery and development.

David Curtin, Waters Vice President of Asia Pacific said, “Our vision is that the training provided at the ASEAN Academy will help grow generic drug manufacturing in the region, and in turn, help provides lower-cost prescription drug options for the people of Southeast Asia.”

Located at the BioInfra headquarters in Seoul, the ASEAN Academy for Bioanalysis will offer hands-on training using the latest analytical instruments and software from Waters. Trainees will focus on the bioanalytical aspect of bioequivalence trials to ensure they are conducted according to the applicable principles of Good Laboratory Practice (GLP).

Bioanalytical methods used today require samples to be well-characterized, fully validated, and documented to yield reliable results that can be satisfactorily interpreted. These skills will help enhance the regional scientific competitiveness and the quality of pharmaceutical research and testing needed to meet the region’s growing demands for access to clinical trials and generic drugs, which are fueled by rising elderly populations facing acute and chronic illnesses.